Surrogate endpoints in liver surgery related trials: A systematic review of the literature

HPB

Volumn 15, Issue 5, 2013, Pages 327-336

  Mpabanzi, Liliane ^a,b   Van Mierlo, Kim M C ^a   Malagõ, Massimo ^b   Dejong, Cornelis H C ^a   Lytras, Dimitrios ^b   Olde Damink, Steven W M ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BECLIN 1; C REACTIVE PROTEIN; CASPASE; GAMMA GLUTAMYLTRANSFERASE; LACTIC ACID; MALONALDEHYDE; MYELOPEROXIDASE; PROTEIN BCL 2; PYRUVIC ACID; UREA;

ANAEROBIC METABOLISM; APOPTOSIS; CHOLESTASIS; CLINICAL STUDY; EXPERIMENTAL STUDY; HUMAN; INFLAMMATION; INFORMATION RETRIEVAL; LABORATORY TEST; LIVER CELL; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER PERFUSION; LIVER RESECTION; LIVER SURGERY; LIVER TRANSPLANTATION; MEDLINE; NEUTROPHIL; OUTCOME ASSESSMENT; OXIDATIVE STRESS; OXYGEN TENSION; PARAMETERS; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; SURROGATE ENDPOINT; SYSTEMATIC REVIEW; UREA CYCLE; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HEPATECTOMY; HUMANS; LIVER FUNCTION TESTS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS;

EID: 84876020526     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00590.x     Document Type: Review

References (81)

1. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 236: 397-406. discussion 6-7.
2. Pulitano C, Aldrighetti L, Arru M, Finazzi R, Catena M, Guzzetti E, et al. (2007) Preoperative methylprednisolone administration maintains coagulation homeostasis in patients undergoing liver resection: importance of inflammatory cytokine modulation. Shock 28: 401-405.
3. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. (1999) Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 3: 1-143.
4. Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien PA, Reeves BC, et al. (2009) Challenges in evaluating surgical innovation. Lancet 374: 1097-1104.
5. Jacquier I, Boutron I, Moher D, Roy C, Ravaud P,. (2006) The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement: a systematic review. Ann Surg 244: 677-683.
6. Solomon MJ, McLeod RS,. (1993) Clinical studies in surgical journals-have we improved? Dis Colon Rectum 36: 43-48.
7. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. (2008) Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337: a2390.
8. van den Broek MA, van Dam RM, Malago M, Dejong CH, van, Breukelen GJ, Damink SW,. (2009) Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint. Br J Surg 96: 1005-1014.
9. Ellenberg SS,. (1993) Surrogate endpoints. Br J Cancer 68: 457-459.
10. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H,. (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1: 49-67.
11. Molenberghs G, Geys H, Buyse M,. (2001) Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Stat Med 20: 3023-3038.
12. Prentice RL,. (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431-440.
13. Fleming TR, DeMets DL,. (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125: 605-613.
14. Gluud C, Brok J, Gong Y, Koretz RL,. (2007) Hepatology may have problems with putative surrogate outcome measures. J Hepatol 46: 734-742.
15. Boissel JP, Collet JP, Moleur P, Haugh M,. (1992) Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 43: 235-244.
16. Kaido T, Uemoto S,. (2008) Quality assessment of randomized controlled trials involving liver surgery. Hepatogastroenterology 55: 1678-1680.
17. Sharma R, Gibbs JF,. (2010) Recent advances in the management of primary hepatic tumors refinement of surgical techniques and effect on outcome. J Surg Oncol 101: 745-754.
18. Kamel SI, de Jong MC, Schulick RD, Diaz-Montes TP, Wolfgang CL, Hirose K, et al. (2011) The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma. World J Surg 35: 1345-1354.
19. Pulitano C, Bodingbauer M, Aldrighetti L, de, Jong MC, Castillo F, Schulick RD, et al. (2011) Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol 18: 1380-1388.
20. de Jong MC, Mayo SC, Pulitano C, Lanella S, Ribero D, Strub J, et al. (2009) Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 13: 2141-2151.
21. van den Broek MA, van Dam RM, van Breukelen GJ, Bemelmans MH, Oussoultzoglou E, Pessaux P, et al. (2011) Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg 98: 1138-1145.
22. Ellenberg S, Hamilton JM,. (1989) Surrogate endpoints in clinical trials: cancer. Stat Med 8: 405-413.
23. Fleming TR,. (1994) Surrogate markers in AIDS and cancer trials. Stat Med 13: 1423-1435. discussion 37-40.
24. Freemantle N, Calvert M,. (2007) Composite and surrogate outcomes in randomised controlled trials. BMJ 334: 756-757.
25. Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H,. (2005) Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 6: 3.
26. Ellenberg SS,. (2001) Surrogate endpoints: the debate goes on. Pharmacoepidemiol Drug Saf 10: 493-496.
27. Alonso A, Molenberghs G, Geys H, Buyse M, Vangeneugden T,. (2006) A unifying approach for surrogate marker validation based on Prentice's criteria. Stat Med 25: 205-221.
28. Freedman LS, Graubard BI, Schatzkin A,. (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167-178.
29. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. (2005) The '50-50 criteria' on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242: 824-828.
30. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. (2007) Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204: 854-862. discussion 62-4.
31. Busse WW, Morgan WJ, Taggart V, Togias A,. (2012) Asthma outcomes workshop: overview. J Allergy Clin Immunol 129 (Suppl.): S1-S8.
32. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. (2012) Asthma outcomes: biomarkers. J Allergy Clin Immunol 129 (Suppl.): S9-S23.
33. Cloutier MM, Schatz M, Castro M, Clark N, Kelly HW, Mangione-Smith R, et al. (2012) Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 129 (Suppl.): S24-S33.
34. Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG,. (2012) Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 30: 1857-1863.
35. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A,. (2008) Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 70: 59-66.
36. Taura P, Fuster J, Mercadal J, Martinez-Palli G, Fondevila C, Blasi A, et al. (2010) The use of beta-adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection. J Hepatol 52: 340-347.
37. Pietsch UC, Herrmann ML, Uhlmann D, Busch T, Hokema F, Kaisers UX, et al. (2010) Blood lactate and pyruvate levels in the perioperative period of liver resection with Pringle maneuver. Clin Hemorheol Microcirc 44: 269-281.
38. Domart MC, Esposti DD, Sebagh M, Olaya N, Harper F, Pierron G, et al. (2009) Concurrent induction of necrosis, apoptosis, and autophagy in ischemic preconditioned human livers formerly treated by chemotherapy. J Hepatol 51: 881-889.
39. Xia F, Wang S, Chen M, Wang X, Feng X, Dong J,. (2009) Protective effect of Verapamil on hepatic ischemia-reperfusion injury during hepatectomy in the cirrhotic patients with hepatocellular carcinoma. Langenbecks Arch Surg 394: 1041-1046.
40. de Liguori Carino N, O'Reilly DA, Dajani K, Ghaneh P, Poston GJ, Wu AV,. (2009) Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure. Eur J Surg Oncol 35: 957-962.
41. Arkadopoulos N, Kostopanagiotou G, Theodoraki K, Farantos C, Theodosopoulos T, Stafyla V, et al. (2009) Ischemic preconditioning confers antiapoptotic protection during major hepatectomies performed under combined inflow and outflow exclusion of the liver. A randomized clinical trial. World J Surg 33: 1909-1915.
42. Wen Y, Miao X, Xiong L, Xiong G, Hu J, Zhong D, et al. (2009) Application of hemihepatic vascular occlusion with hanging maneuver in hepatectomy. Hepatogastroenterology 56: 442-446.
43. Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, et al. (2008) A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg 248: 909-918.
44. Akita H, Sasaki Y, Yamada T, Gotoh K, Ohigashi H, Eguchi H, et al. (2008) Real-time intraoperative assessment of residual liver functional reserve using pulse dye densitometry. World J Surg 32: 2668-2674.
45. Ko JS, Gwak MS, Choi SJ, Kim GS, Kim JA, Yang M, et al. (2008) The effects of desflurane and propofol-remifentanil on postoperative hepatic and renal functions after right hepatectomy in liver donors. Liver Transpl 14: 1150-1158.
46. Scheingraber S, Richter S, Igna D, Flesch S, Kopp B, Schilling MK,. (2008) Indocyanine green disappearance rate is the most useful marker for liver resection. Hepatogastroenterology 55: 1394-1399.
47. Kim YI, Fujita S, Hwang YJ, Chun JM, Song KE, Chun BY,. (2007) Successful intermittent application of the Pringle maneuver for 30 minutes during human hepatectomy: a clinical randomized study with use of a protease inhibitor. Hepatogastroenterology 54: 2055-2060.
48. Tang LJ, Tian FZ, Gao XM,. (2002) Hepatocellular glycogen in alleviation of liver ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int 1: 532-535.
49. Tang L, Tian F, Tao W, Cui J,. (2007) Hepatocellular glycogen in alleviation of liver ischemia-reperfusion injury during partial hepatectomy. World J Surg 31: 2039-2043.
50. Brooks AJ, Hammond JS, Girling K, Beckingham IJ,. (2007) The effect of hepatic vascular inflow occlusion on liver tissue pH, carbon dioxide, and oxygen partial pressures: defining the optimal clamp/release regime for intermittent portal clamping. J Surg Res 141: 247-251.
51. Kostopanagiotou G, Pandazi A, Matsota P, Arkadopoulos N, Dalamanga N, Politou M, et al. (2007) Effect of packed red blood cells transfusion on plasma fibronectin during liver resection. Transfus Med 17: 115-118.
52. Schmidt SC, Hamann S, Langrehr JM, Hoflich C, Mittler J, Jacob D, et al. (2007) Preoperative high-dose steroid administration attenuates the surgical stress response following liver resection: results of a prospective randomized study. J Hepatobiliary Pancreat Surg 14: 484-492.
53. Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA,. (2006) A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg 244: 921-928. discussion 8-30.
54. Kostopanagiotou G, Pandazi AK, Andreadou I, Markantonis SL, Niokou D, Teloudis A, et al. (2006) Effects of mannitol in the prevention of lipid peroxidation during liver resection with hepatic vascular exclusion. J Clin Anesth 18: 570-574.
55. Theodoraki K, Arkadopoulos N, Fragulidis G, Voros D, Karapanos K, Markatou M, et al. (2006) Transhepatic lactate gradient in relation to liver ischemia/reperfusion injury during major hepatectomies. Liver Transpl 12: 1825-1831.
56. Dunschede F, Erbes K, Kircher A, Westermann S, Seifert J, Schad A, et al. (2006) Reduction of ischemia reperfusion injury after liver resection and hepatic inflow occlusion by alpha-lipoic acid in humans. World J Gastroenterol 12: 6812-6817.
57. Esaki M, Sano T, Shimada K, Sakamoto Y, Takahashi Y, Wakai K, et al. (2006) Randomized clinical trial of hepatectomy using intermittent pedicle occlusion with ischaemic intervals of 15 versus 30 minutes. Br J Surg 93: 944-951.
58. Azoulay D, Lucidi V, Andreani P, Maggi U, Sebagh M, Ichai P, et al. (2006) Ischemic preconditioning for major liver resection under vascular exclusion of the liver preserving the caval flow: a randomized prospective study. J Am Coll Surg 202: 203-211.
59. Kim YI, Chung HJ, Song KE, Hwang YJ, Lee JW, Lee YJ, et al. (2006) Evaluation of a protease inhibitor in the prevention of ischemia and reperfusion injury in hepatectomy under intermittent Pringle maneuver. Am J Surg 191: 72-76.
60. Sugimoto H, Okochi O, Hirota M, Kanazumi N, Nomoto S, Inoue S, et al. (2006) Early detection of liver failure after hepatectomy by indocyanine green elimination rate measured by pulse dye-densitometry. J Hepatobiliary Pancreat Surg 13: 543-548.
61. Figueras J, Llado L, Ruiz D, Ramos E, Busquets J, Rafecas A, et al. (2005) Complete versus selective portal triad clamping for minor liver resections: a prospective randomized trial. Ann Surg 241: 582-590.
62. Chouker A, Martignoni A, Schauer RJ, Dugas M, Schachtner T, Kaufmann I, et al. (2005) Alpha-gluthathione S-transferase as an early marker of hepatic ischemia/reperfusion injury after liver resection. World J Surg 29: 528-534.
63. Chouker A, Martignoni A, Schauer R, Dugas M, Rau HG, Jauch KW, et al. (2005) Beneficial effects of ischemic preconditioning in patients undergoing hepatectomy: the role of neutrophils. Arch Surg 140: 129-136.
64. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, et al. (2005) Effect of the herbal medicine Dai-kenchu-to for serum ammonia in hepatectomized patients. Hepatogastroenterology 52: 161-165.
65. Bartels M, Biesalski HK, Engelhart K, Sendlhofer G, Rehak P, Nagel E,. (2004) Pilot study on the effect of parenteral vitamin E on ischemia and reperfusion induced liver injury: a double blind, randomized, placebo-controlled trial. Clin Nutr 23: 1360-1370.
66. Li SQ, Liang LJ, Huang JF, Li Z,. (2004) Ischemic preconditioning protects liver from hepatectomy under hepatic inflow occlusion for hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 10: 2580-2584.
67. Nishiyama T, Fujimoto T, Hanaoka K,. (2004) A comparison of liver function after hepatectomy in cirrhotic patients between sevoflurane and isoflurane in anesthesia with nitrous oxide and epidural block. Anesth Analg 98: 990-993. table of contents.
68. Nuzzo G, Giuliante F, Vellone M, De Cosmo G, Ardito F, Murazio M, et al. (2004) Pedicle clamping with ischemic preconditioning in liver resection. Liver Transpl 10 (Suppl. 1): S53-S57.
69. Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V, et al. (2003) A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg 238: 843-850. discussion 51-2.
70. Smyrniotis V, Kostopanagiotou G, Lolis E, Theodoraki K, Farantos C, Andreadou I, et al. (2003) Effects of hepatovenous back flow on ischemic- reperfusion injuries in liver resections with the pringle maneuver. J Am Coll Surg 197: 949-954.
71. Wu FP, Boelens PG, van, Leeuwen PA, Hoekman K, Hansma AH, Wiezer MJ, et al. (2003) Effects of major liver resection, with or without recombinant bactericidal/permeability-increasing protein (rBPI21), on the angiogenic profile of patients with metastatic colorectal carcinoma. J Surg Oncol 84: 137-142.
72. Capussotti L, Nuzzo G, Polastri R, Giuliante F, Muratore A, Giovannini I,. (2003) Continuous versus intermittent portal triad clamping during hepatectomy in cirrhosis. Results of a prospective, randomized clinical trial. Hepatogastroenterology 50: 1073-1077.
73. Man K, Lo CM, Liu CL, Zhang ZW, Lee TK, Ng IO, et al. (2003) Effects of the intermittent Pringle manoeuvre on hepatic gene expression and ultrastructure in a randomized clinical study. Br J Surg 90: 183-189.
74. Muratore A, Ribero D, Ferrero A, Bergero R, Capussotti L,. (2003) Prospective randomized study of steroids in the prevention of ischaemic injury during hepatic resection with pedicle clamping. Br J Surg 90: 17-22.
75. Vriens MR, Marinelli A, Harinck HI, Zwinderman KH, van de, Velde CJ,. (2002) The role of allopurinol in human liver ischemia/reperfusion injury: a prospective randomized clinical trial. Hepatogastroenterology 49: 1069-1073.
76. Kim YI, Hwang YJ, Song KE, Yun YK, Lee JW, Chun BY,. (2002) Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver. J Am Coll Surg 195: 41-50.
77. Okochi O, Kaneko T, Sugimoto H, Inoue S, Takeda S, Nakao A,. (2002) ICG pulse spectrophotometry for perioperative liver function in hepatectomy. J Surg Res 103: 109-113.
78. Wiezer MJ, Boelens PG, Vuylsteke RJ, Nijveldt RJ, Meijer C, Cuesta MA, et al. (2001) Perioperative treatment with bactericidal/permeability-increasing protein (rBPI21) in major liver surgery: a concise summary. Ann Acad Med Singapore 30: 226-233.
79. Orii R, Sugawara Y, Hayashida M, Uchida K, Yamada Y, Takayama T, et al. (2001) Lactate is correlated with the indocyanine green elimination rate in liver resection for cirrhotic patients. Anesth Analg 92: 1064-1070.
80. Noie T, Sugawara Y, Harihara Y, Takayama T, Kubota K, Ohashi Y, et al. (2001) Kinetics of urinary trypsin inhibitor in patients undergoing partial hepatectomy. Scand J Gastroenterol 36: 410-416.
81. Yamashita Y, Shimada M, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, et al. (2001) Effects of preoperative steroid administration on surgical stress in hepatic resection: prospective randomized trial. Arch Surg 136: 328-333.